SUBSTANTIAL REDUCTION IN CHRONIC GRAFT-VERSUS-HOST DISEASE AND ADEQUATE IMMUNE RECONSTITUTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN UNRELATED DONOR TRANSPLANTATION: A COMPARATIVE CASE-CONTROL STUDY (EHA 2025) - May 16, 2025 - Abstract #PB3405; "Study group included 61 consecutive patients who underwent MUD-HCT between 01/2021 and 09/2024 for myeloid malignancies with PTCy (50mg/kg on days +3 and +4) in addition to tacrolimus/mycophenolate mofetil (MMF) as GvHD prophylaxis. Conditioning regimen was busulfan/fludarabine/thiotepa...There was no difference in the CIN of CMV viremia between the PTCy and the control group for patients who received letermovir prophylaxis (20.6% vs. 24.0%, respectively, p=0.73)... We implemented PTCy for GvHD prophylaxis in the context of MUD-HCT and compared its efficacy to conventional non-PTCy-based strategies. The use of PTCy was not linked to delayed immune reconstitution or increased risk of viral reactivation. Moreover, PTCy was associated with substantial reduction in the occurrence of chronic GvHD, which translated to improved GRFS."
Clinical • Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • Transplantation • CD4
|
|
Antri Polyviou; Sotirios Bristogiannis; Athanasios Gakopoulos; Michael Panoussieris; Soultana Tryfonidou; Panagiotis Siamatas; Ioanna Venetsanaki; Eleni Porfyriou; Maria-Eleni Karatza; Eirini Grispou; Maria Garofalaki; Eirini Tziotziou; Tatiana Tzenou; Georgia Kourti; Ifigeneia Tzannou; Ioannis Tsonis; Stavros Gigantes; Ioannis Baltadakis
|